Mamedica CEO, Jon Robson and Cookies co-founder and CEO, Berner, discuss the impact of this landmark collaboration for access to medical cannabis in the UK
Mamedica the nation’s leading medical cannabis clinic, servicing nearly 10,000 patients – has today announced an exclusive partnership with Cookies, the world’s most recognised cannabis brand, to offer its premium pharmaceutical products to patients across the UK. Through this agreement, Mamedica will serve as the official licence holder and distributor of Cookies’ medical cannabis products in the UK, supplied by SOMAÍ Group. This partnership marks a major milestone in Britain’s medical cannabis landscape, providing patients with access to internationally renowned genetics that meet the highest pharmaceutical-grade standards.
The UK’s medical cannabis market has seen significant growth since its legalisation in 2018, with an estimated 80,000 people now actively receiving cannabis-based prescription medicines (CBPMs) as an alternative to traditional medication. Mamedica is at the forefront of this rapidly expanding sector, achieving a 1,250% increase in patient numbers in 2023, followed by a further 154% growth in 2024. Recent analysis from the clinic has found that while a third of the nation would like access to medical cannabis for an ailment, almost 18 million Brits believe the legislation surrounding medical cannabis to be too prohibitive and needs change.
Broadening access to medical cannabis in the UK, the collaboration will ensure that patients can be legally prescribed Cookies’ signature strains – known for their unique terpene profiles and genetics. Cultivated and processed in accordance with EU-GMP (Good Manufacturing Practice) and GACP (Good Agricultural and Collection Practice) standards, these products offer patients a consistent and high-quality medical cannabis option.
By partnering with globally recognised brands such as Cookies, Mamedica is not only expanding patient choice, but also evolving the conversation around symptomatic relief in the UK, ensuring more people can benefit from safe, high-quality cannabis-based treatments. Cookies’ products are now available via prescription through Mamedica and partner pharmacies.
Jon Robson, CEO and founder of Mamedica, discusses the significance of this partnership for UK patients: “This partnership with Cookies signals a new era for UK medical cannabis patients. By combining Mamedica’s clinical expertise with Cookies’ world-class genetics and brand heritage, we’re delivering premium cannabis products backed by science, safety, and patient-centred care.
“I first visited a Cookies Dispensary in California exactly six years ago this week, and I’ve followed the brand’s incredible journey ever since. So, when the opportunity arose nearly two years ago to bring Cookies to the UK, we didn’t hesitate. It’s a full-circle moment — and just the beginning. “
Berner, Founder and CEO of Cookies, added: “We’re excited to partner with Mamedica to bring Cookies to the UK medical cannabis space. Our goal has always been to make our genetics accessible to patients globally, and the UK is a key part of that mission.”
